Patient-derived ovarian cancer organoids capture the genomic profiles of primary tumours applicable for drug sensitivity and resistance testing
- Nanki, Yoshiko
- Chiyoda, Tatsuyuki
- Hirasawa, Akira
- Ookubo, Aki
- Itoh, Manabu
- Ueno, Masaru
- Akahane, Tomoko
- Kameyama, Kaori
- Yamagami, Wataru
- Kataoka, Fumio
- Aoki, Daisuke
DOIAbstract
The use of primary patient-derived organoids for drug sensitivity and resistance testing could play an important role in precision cancer medicine. We developed expandable ovarian cancer organoids in<3 weeks; these organoids captured the characteristics of histological cancer subtypes and replicated the mutational landscape of the primary tumours. Seven pairs of organoids (3 high-grade serous, 1 clear cell, 3 endometrioid) and original tumours shared 59.5% (36.1-73.1%) of the variants identified. Copy number variations were also similar among organoids and primary tumours. The organoid that harboured the BRCA1 pathogenic variant (p.L63*) showed a higher sensitivity to PARP inhibitor, olaparib, as well as to platinum drugs compared to the ot...
Add to ORKG